
## Yasuhiro Ikeda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3818079/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. Journal of Cardiology, 2020, 75, 454-461.	1.9	13
2	How to Avoid Adverse Events During Apixaban Therapy in Patients With Atrial Fibrillation. Circulation Journal, 2015, 79, 2539-2540.	1.6	1
3	A cell-penetrating phospholamban-specific RNA aptamer enhances Ca2+ transients and contractile function in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2014, 76, 177-185.	1.9	15
4	Association of Apixaban Therapy and Prothrombin Time in Patients With Atrial Fibrillation. Circulation Journal, 2014, 78, 2651-2656.	1.6	15
5	Tenascin C protects aorta from acute dissection in mice. Scientific Reports, 2014, 4, 4051.	3.3	43
6	Important role of the angiotensin II pathway in producing matrix metalloproteinase-9 in human thoracic aortic aneurysms. Journal of Surgical Research, 2013, 183, 472-477.	1.6	43
7	Periostin Links Mechanical Strain to Inflammation in Abdominal Aortic Aneurysm. PLoS ONE, 2013, 8, e79753.	2.5	52
8	BNP-promoter Driven-and AAV9 Mediated-suppression of Protein Phosphatase 1β Halts Pressure-overload Induced Heart Failure in Mice. Journal of Cardiac Failure, 2012, 18, S169.	1.7	0
9	Heart Failure-Inducible Gene Therapy Targeting Protein Phosphatase 1 Prevents Progressive Left Ventricular Remodeling. PLoS ONE, 2012, 7, e35875.	2.5	29
10	Revision Points and Remaining Issues to be Solved in the Updated Guidelines for Treatment of Chronic Heart Failure. Journal of Cardiac Failure, 2011, 17, S131.	1.7	0
11	Effects of Oral Tolvaptan Administration in Patients Hospitalized for Chronic Heart Failure with Preserved Ejection Fraction and Chronic Kidney Disease. Journal of Cardiac Failure, 2011, 17, S152.	1.7	0
12	Tenascin  is expressed in abdominal aortic aneurysm tissue with an active degradation process. Pathology International, 2011, 61, 559-564.	1.3	30
13	Tongue Muscle-Derived Stem Cells Express Connexin 43 and Improve Cardiac Remodeling and Survival After Myocardial Infarction in Mice. Circulation Journal, 2010, 74, 1219-1226.	1.6	18
14	Catecholaminergic Polymorphic Ventricular Tachycardia Is Caused by Mutation-Linked Defective Conformational Regulation of the Ryanodine Receptor. Circulation Research, 2010, 106, 1413-1424.	4.5	138
15	Protein Phosphatase 1β is Critical to Determine Cardiac Systolic and Diastolic Function in Cardiomyopathic Mice. Journal of Cardiac Failure, 2010, 16, S165.	1.7	0
16	Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction. Biochemical and Biophysical Research Communications, 2010, 394, 660-666.	2.1	69
17	Lysyl oxidase resolves inflammation by reducing monocyte chemoattractant protein-1 in abdominal aortic aneurysm. Atherosclerosis, 2010, 208, 366-369.	0.8	42
18	Dantrolene Improves Cardiac Contractile Function by Inhibiting SR Ca2+ Leak in Failing Hearts. Journal of Cardiac Failure, 2009, 15, S172.	1.7	0

Yasuhiro Ikeda

#	Article	IF	CITATIONS
19	In Vivo RNA Interference of Protein Phosphatase 1 Beta Augments Cardiac Contracitility in Mice. Journal of Cardiac Failure, 2009, 15, S175.	1.7	0
20	lschemic Pre-Conditioning Enhances the Mobilization and Recruitment of Bone Marrow Stem Cells to Protect Against Ischemia/Reperfusion Injury in the Late Phase. Journal of the American College of Cardiology, 2009, 53, 1814-1822.	2.8	95
21	Inhibitor-1 is Potential Target for Enhancing Sarcoplasmic Reticulum Ca2+ Loading in Failing Hearts. Circulation Journal, 2009, 73, 1018-1019.	1.6	0
22	Regression of Abdominal Aortic Aneurysms through Pharmacologic Therapy. , 2009, , 43-49.		0
23	Phosphorylation Regulation of Sarcoplasmic Reticulum Microdomain in Heart Failure. Journal of Cardiac Failure, 2008, 14, S146.	1.7	0
24	Enhanced Sensitivity of Ryanodine Receptor to Activation by Luminal Ca2+ may underlie the pathogenic mechanism of lethal arrhythmia. Journal of Cardiac Failure, 2008, 14, S155.	1.7	0
25	Protein Phosphatase 1 beta is Most Abundant Isoform in the Longitudinal Sarcoplasmic Reticulum and Regulates Phospholamban Phosphorylation in Cardiomyocytes. Journal of Cardiac Failure, 2008, 14, S172.	1.7	0
26	Perinatal Loss of Nkx2-5 Results in Rapid Conduction and Contraction Defects. Circulation Research, 2008, 103, 580-590.	4.5	86
27	Lentiviral Vector–mediated SERCA2 Gene Transfer Protects Against Heart Failure and Left Ventricular Remodeling After Myocardial Infarction in Rats. Molecular Therapy, 2008, 16, 1026-1032.	8.2	80
28	Defective Ca <sup>2+</sup> Cycling as a Key Pathogenic Mechanism of Heart Failure. Circulation Journal, 2008, 72, A22-A30.	1.6	13
29	Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure. Physiology, 2008, 23, 6-16.	3.1	32
30	Heart Failure: Pathophysiology. , 2008, , 27-48.		2
31	Comparison of Cell Therapy and Cytokine Therapy for Functional Repair in Ischemic and Nonischemic Heart Failure. Cell Transplantation, 2007, 16, 365-374.	2.5	21
32	Exploration of Gene Therapy for Treatment of Heart Failure. Journal of Cardiac Failure, 2007, 13, S6.	1.7	0
33	Defective Domain-Domain Interaction Between C-terminal and Central Regions of Ryanodine Receptor as a Critical Cause of Diastolic Ca2+ Spark in Canine Cardiomyocytes. Journal of Cardiac Failure, 2007, 13, S54-S55.	1.7	0
34	Spontaneous Ca2+ Sparks Through Mutated Ryanodine Receptor as a Critical Cause of Catecholaminergic Polymorphic Ventricular Tachycardia. Journal of Cardiac Failure, 2007, 13, S55.	1.7	0
35	Scavenging Free Radicals by Low-Dose Carvedilol Prevents Redox-Dependent Ca2+Leak Via Stabilization of Ryanodine Receptor in Heart Failure. Journal of the American College of Cardiology, 2007, 49, 1722-1732.	2.8	125
36	Progression of Heart Failure Was Suppressed by Inhibition of Apoptosis Signal-Regulating Kinase 1 Via Transcoronary Gene Transfer. Journal of the American College of Cardiology, 2007, 50, 453-462.	2.8	35

YASUHIRO IKEDA

#	Article	lF	CITATIONS
37	Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 43-52.	3.3	99
38	Translocation of Protein Phosphatase 1 with Inhibitor-2 from Sarcoplasmic Reticulum to Cytosol Augments Ca2+ Cycling in Cardiomyocytes. Journal of Cardiac Failure, 2006, 12, S163.	1.7	0
39	Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H886-H893.	3.2	264
40	Regression of Abdominal Aortic Aneurysm by Inhibition of c-Jun N-Terminal Kinase in Mice. Annals of the New York Academy of Sciences, 2006, 1085, 74-81.	3.8	54
41	Identification of c-Jun N-Terminal Kinase as a Therapeutic Target for Abdominal Aortic Aneurysm. Annals of the New York Academy of Sciences, 2006, 1085, 403-406.	3.8	17
42	Inhibition of protein phosphatase 1 by inhibitorâ€2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB Journal, 2006, 20, 1197-1199.	0.5	77
43	Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nature Medicine, 2005, 11, 1330-1338.	30.7	385
44	Correction of Defective Interdomain Interaction Within Ryanodine Receptor by Antioxidant Is a New Therapeutic Strategy Against Heart Failure. Circulation, 2005, 112, 3633-3643.	1.6	110
45	Defective Regulation of Interdomain Interactions Within the Ryanodine Receptor Plays a Key Role in the Pathogenesis of Heart Failure. Circulation, 2005, 111, 3400-3410.	1.6	131
46	Identification of a Molecular Therapeutic Target for Abdominal Aortic Aneurysm. Journal of Cardiac Failure, 2005, 11, S248.	1.7	0
47	Increased Protein Phosphatase 1 Activity as a New Therapeutic Target of Heart Failure in Genetic Cardiomyopathy. Journal of Cardiac Failure, 2005, 11, S250.	1.7	0
48	Chronic Inhibition of Apoptosis Signal-regulating Kinase 1 (ASK-1) by Myocardial Gene Transfer Suppressed Progression of Heart Failure in Genetic Cardiomyopathy. Journal of Cardiac Failure, 2005, 11, S279.	1.7	0
49	Regulation of Left Ventricular Remodeling and Regeneration by ACE Inhibitor Following Donor Heart Myocardial Infarction with Heterotopic Transplant-Coronary Ligation Model. Journal of Cardiac Failure, 2005, 11, S291.	1.7	0
50	Altered intracellular Ca2+ handling in heart failure. Journal of Clinical Investigation, 2005, 115, 556-564.	8.2	184
51	Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. Journal of Clinical Investigation, 2004, 113, 727-736.	8.2	141
52	Restoration of Deficient Membrane Proteins in the Cardiomyopathic Hamster by In Vivo Cardiac Gene Transfer. Circulation, 2002, 105, 502-508.	1.6	99
53	Effect of Ischemic Preconditioning and Mitochondrial KATP Channel Openers on Chronic Left Ventricular Remodeling in the Ischemic-Reperfused Rat Heart Circulation Journal, 2002, 66, 411-415.	1.6	23
54	Apoptosis and oncosis in the early progression of left ventricular dysfunction in the cardiomyopathic hamster. Basic Research in Cardiology, 2002, 97, 65-75.	5.9	21

YASUHIRO IKEDA

#	Article	IF	CITATIONS
55	Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature, 2002, 415, 171-175.	27.8	580
56	Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nature Medicine, 2002, 8, 864-871.	30.7	344
57	A Defect in the Kv Channel-Interacting Protein 2 (KChIP2) Gene Leads to a Complete Loss of Ito and Confers Susceptibility to Ventricular Tachycardia. Cell, 2001, 107, 801-813.	28.9	408
58	Effects of In Vivo Gene Transfer of Fibroblast Growth Factor-2 on Cardiac Function and Collateral Vessel Formation in the Microembolized Rabbit Heart. Japanese Circulation Journal, 2001, 65, 226-231.	1.0	14
59	Models of Cardiac Disease in the Mouse. Developments in Cardiovascular Medicine, 2001, , 335-352.	0.1	1
60	Models of dilated cardiomyopathy in the mouse and the hamster. Current Opinion in Cardiology, 2000, 15, 197-201.	1.8	35
61	Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H1362-H1370.	3.2	43
62	Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control. International Journal of Cardiology, 1999, 68, 47-56.	1.7	7
63	Regional diastolic function in effort angina pectoris: Assessment with biplane left ventriculography. Heart and Vessels, 1995, 10, 87-95.	1.2	3
64	Baroreflex gains the velocity of blood pressure regulation through the neural traffic in anesthetized rabbits. Pathophysiology, 1994, 1, 324.	2.2	0
65	Left Ventricular Diastolic Function in Effort Angina Pectoris. , 1992, , 135-137.		0